PIK3CA and lung carcinoma: These fusions result in the production of potent oncogenic drivers that promote cell proliferation, activation, and cell cycle progression by activating downstream signaling pathways, accelerating the development and progression of lung carcinoma due to the upregulation of JAK/STAT, PI3K/AKT, and MAPK/ERK signaling pathways [84].